Jon Walsh, founder, chief scientific officer, Unlearn, explains how regulators are clarifying best practices for integrating AI and digital twins into clinical research.

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma ...

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That ...

The Veterinary API Manufacturing market presents opportunities in expanding companion animal care, demand for livestock ...

LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its ...

STATEN ISLAND, N.Y., Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...

Market to Reach $430 Million by 2032, Driven by Breakthrough Clinical Trials and Expanding Indications. The global RNA-Based Therape ...

KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the ...

Valneva recorded an operating loss of €16.8 million in the first half of 2025 compared to an operating profit of €46.7 million in the first half of 2024. The decrease was mainly the result of the PRV ...

DelveInsight's IBAT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Translating research into improved patient care practices and products assumes that the underlying and cumulative research is ...

VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company ...